News and Press Releases
ADOA PROGRAM – PRESENTATION AT NANOS 2026
PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available One of PYC’s clinical-stage programs is an investigational...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2026
Emmes Coordinates Groundbreaking Stem-Cell Ophthalmology Trial
18 February 2026 -- Maryland, US -- Emmes, a full-service, global Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation – in collaboration with the UC Davis Eye...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 18, 2026
Samsung Bioepis Reaches Settlement Agreement for Eylea (Aflibercept) Biosimilar in Europe and the Rest of the World
30 January 2026 -- Incheon, Korea -- Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Regeneron and Bayer concerning the commercialization of SB15, a biosimilar to...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2026
Stratasys Digital Anatomy Technology Powers First 3D-Printed Eyelid Surgery Training Models in Europe
Addion and the University of Innsbruck advance surgical education with life-like anatomical models that enhance the skill sets of medical professionals and improve patient outcomes 18 November 2025 -- Minnesota,...
Category: Biotechnology, Other, Pharmaceutical
Posted: November 18, 2025
Acuitas Therapeutics to Showcase LNP Delivery Platform at Four Prestigious Conferences in November 2025
29 October 2025 -- British Columbia, Canada -- Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems, today announced its participation in four upcoming conferences in November 2025....
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: November 11, 2025
Santen Launches SETANEO Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension
23 October 2025 -- Osaka, Japan -- Santen Pharmaceutical Co., Ltd announced today that it launched SETANEO Ophthalmic Solution 0.002% (generic name: sepetaprost; hereafter the product) in Japan, for the...
Category: Drug Delivery, Other, Pharmaceutical
Posted: October 23, 2025
Horus Pharma announces strategic Agreement to commercialize Formycon’s Aflibercept Biosimilar FYB203 under the brand name Baiama across Key European Markets including its Home Market France
23 October 2025 -- Nice, France -- Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading player in Europe, today announced that it has entered into...
Category: Logistics, Other, Pharmaceutical
Posted: October 23, 2025
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings 16 October 2025 -- New Jersey, US -- ANI Pharmaceuticals, Inc today announced that results from...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 16, 2025
Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611
14 October 2025 -- Paris, France -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology welcomes the publication of new data...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon and its partners entered into a settlement and license agreement with Regeneron for FYB203/AHZANTIVE (Aflibercept-mrbb) Pending litigation at the U.S. District Court for the Northern District of West Virginia...
Category: Logistics, Other, Pharmaceutical
Posted: October 2, 2025
Biocon Biologics Secures U.S. Market Entry Date for Bosaya and Aukelso, Denosumab Biosimilars
1 October 2025 -- Bengaluru, India and New Jersey, US -- Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced a settlement and...
Category: Logistics, Other, Pharmaceutical
Posted: October 1, 2025
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
22 September 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 22, 2025
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 15, 2025
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
4 September 2025 -- Paris, France -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will...
Category: Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: September 4, 2025
Fidia Farmaceutici enters the UK market with the acquisition of Altacor Ltd
Marking another significant milestone in its ongoing international expansion, the Company enters the rapidly-growing UK ophthalmology market, a key therapeutic area for the Group 3 September 2025 -- Abano Terme,...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 3, 2025
